Previous Close | 4.35 |
Open | 4.30 |
Bid | 4.15 x 1500 |
Ask | 4.20 x 1600 |
Day's Range | 4.10 - 4.40 |
52 Week Range | 2.25 - 5.40 |
Volume | 134,096 |
Avg. Volume | 318,635 |
Market Cap | 217.531M |
Beta | 1.41 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.72 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 8.40 |
LONDON, UK / ACCESSWIRE / April 19, 2018 / Active-Investors.com has just released a free research report on Compugen Ltd (NASDAQ: CGEN). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=CGEN as the Company's latest news hit the wire. On April 17, 2018, the Company announced that preclinical data presented by Bayer AG at the Annual Meeting of the American Association of Cancer Research (AACR) held April 14-18, 2018, in Chicago, Illinois, highlights the efficacy of BAY 1905254 (formerly the CGEN-15001T program) in cancer immunotherapy.
HOLON, Israel, April 17, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that preclinical data presented by Bayer AG at the Annual Meeting of the American Association of Cancer Research held April 14-18, 2018, in Chicago, Illinois, highlights the efficacy of BAY 1905254 (formerly the CGEN-15001T program) in cancer immunotherapy. BAY 1905254 is a first-in-class therapeutic antibody candidate targeting ILDR2, a novel immune checkpoint discovered by Compugen.
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! SYNNEX Corporation (NYSE: SNX ) stock lost more than ...
Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced it entered into an exclusive license agreement with MedImmune, the global biologics research and development arm of AstraZeneca, to enable the development of bi-specific and multi-specific immuno-oncology antibody products. Under the terms of the agreement, Compugen will provide an exclusive license to MedImmune for the development of bi-specific and multi-specific antibody products derived from a Compugen pipeline program.
Israeli drugmaker Compugen Ltd (CGEN.TA) (CGEN.O) said it had agreed an exclusive licensing deal with a unit of AstraZeneca (AZN.L) to develop antibody products to treat cancer, which could be worth more than $200 million (142.25 million pounds). Under the terms of the deal announced on Monday, MedImmune - the research and development arm of AstraZeneca - will develop genetically engineered antibody products derived from Compugen's oncology drug pipeline and pay royalties to the Israeli firm.
Israeli drugmaker Compugen Ltd said it had agreed an exclusive licensing deal with a unit of AstraZeneca to develop antibody products to treat cancer, which could be worth more than $200 million. Under the terms of the deal announced on Monday, MedImmune - the research and development arm of AstraZeneca - will develop genetically engineered antibody products derived from Compugen's oncology drug pipeline and pay royalties to the Israeli firm.
Compugen Ltd (NASDAQ:CGEN), a life sciences company based in Israel, led the NasdaqGM gainers with a relatively large price hike in the past couple of weeks. Less-covered, small caps tendRead More...
HOLON, Israel, March 26, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced the appointment of Dr. Henry Adewoye, to the newly created position of Chief Medical Officer, effective immediately. Dr. Adewoye brings to Compugen over two decades of extensive and broad experience in leading multiple clinical trials in oncology and hematology in both the biopharmaceutical industry and academia. As Chief Medical Officer, Dr. Adewoye will play a key role in leading the Company's transition into a clinical stage company, and will assume overall responsibility of Compugen's clinical stage pipeline programs.
Compugen Ltd’s (NASDAQ:CGEN) most recent earnings announcement in December 2017 suggested company earnings became less negative compared to the previous year’s level as a result of recent tailwinds Today IRead More...
HOLON, Israel , March 8, 2018 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN ), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that ...
NEW YORK, NY / ACCESSWIRE / February 21, 2018 / Compugen Ltd. (NASDAQ: CGEN ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 21, 2018, at 10:00 AM Eastern Time. ...
The Holon, Israel-based company said it had a loss of 18 cents per share. For the year, the company reported that its loss widened to $37.1 million, or 72 cents per share. The company's shares closed at ...
Phase 1 Trial for COM701 Expected to Start in 2018 Bayer in Late Stage Preclinical Development of CGEN-15001T Program HOLON, Israel , Feb. 21, 2018 /PRNewswire/ -- Compugen Ltd. ( NASDAQ: CGEN ), a leader ...
Stock Monitor: Array BioPharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 08, 2018 / Active-Investors.com has just released a free research report on Compugen Ltd (NASDAQ: CGEN ). If you ...
HOLON, Israel , Feb. 8, 2017 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, announced today that ...
HOLON, Israel, Feb. 6, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced the online publication of the discovery and validation of the ILDR2 protein as a novel immune checkpoint and its use as an Fc fusion protein for the treatment of autoimmune diseases in two peer-reviewed papers in The Journal of Immunology. Antibody-based therapeutics targeting ILDR2, designated by Compugen as CGEN-15001T, for immuno-oncology were licensed to Bayer, while Compugen retains the full rights to the fusion protein, designated as CGEN-15001, consisting of the extracellular domain of ILDR2 and an Fc domain, for potential use in autoimmune diseases.
HOLON, Israel, Jan. 18, 2018 /PRNewswire/ -- Compugen Ltd. (CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced new preclinical data demonstrating distinctive features of the PVRIG pathway and the potential of COM701, a first-in-class therapeutic antibody candidate targeting PVRIG, for treating multiple solid tumors. The data, presented at the Keystone Symposia Conference, A3: T Cell Dysfunction, Cancer and Infection, being held January 16-20, 2018, at the Beaver Run Resort, Breckenridge, CO, provide indication for a dominant role of the PVRIG/TIGIT axis in cancer evasion of immune response in multiple cancers.
HOLON, Israel , January 2, 2018 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced upcoming ...
Compugen Ltd (NASDAQ:CGEN), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is CGEN willRead More...
After looking at Compugen Ltd’s (NASDAQ:CGEN) latest earnings announcement (30 September 2017), I found it useful to revisit the company’s performance in the past couple of years and assess thisRead More...
Compugen Ltd (NASDAQ:CGEN), a life sciences tools and services company based in Israel, received a lot of attention from a substantial price movement on the NasdaqGM in the over theRead More...
NEW YORK, NY / ACCESSWIRE / November 7, 2017 / Compugen Ltd. (NASDAQ: CGEN ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 7, 2017 at 10:00 AM Eastern Time. ...
On a per-share basis, the Holon, Israel-based company said it had a loss of 19 cents. The company's shares closed at $3. A year ago, they were trading at $5.95. _____ This story was generated by Automated ...
- Phase I Study for COM701 Expected to Start in 2018 - IND Application for COM902 Anticipated in 2019 HOLON, Israel , Nov. 7, 2017 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery ...